about
Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary careTreatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastineInternational Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsH1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects--a retrospective survey studyRupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.MALDI-tandem mass spectrometry imaging of astemizole and its primary metabolite in rat brain sections.Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios.Emerging safety issues regarding long-term usage of H(1)receptor antagonists.Update on the cardiac safety of moxifloxacin.Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction.The role and choice criteria of antihistamines in allergy management - expert opinion.Tasimelteon for insomnia.Clinical pharmacists' opportunities to reduce inappropriate prescription of QT-prolonging medications: calls to action.Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model.Biodistribution of diphenhydramine in reproductive organs in an overdose case.Toxicological identification of diphenhydramine (DPH) in suicide.Enhancement of B cell and monocyte populations in rats exposed to chlorpheniramine.
P2860
Q24670611-3034D352-D109-4379-869B-62D269B2AFB7Q26750723-60755B30-2208-4E5D-8C7C-24B5959BE478Q26827568-82628FE8-D952-41C8-9220-78050740872EQ28740885-BF66D33A-DAA8-46B9-AC02-DA0F8801CDE2Q30475256-E1D4B1B7-CC5E-4A68-9698-E4D914F1B56BQ33748863-434EF5E7-400C-4C36-BE3A-BC0086864CAFQ34982550-541E4306-A64B-4B84-8635-10440CDC11FAQ35194475-558C032F-2DC3-401B-B3CB-70924D0072F2Q36345861-E099EBEB-3D1E-402F-8128-378197FBA3E9Q36826600-E2F5A15A-5C4A-4391-AC96-BB6286C16D12Q37531868-CA8AB59D-5F4D-43F2-83A2-D0B0782F6892Q37872781-282C5AF6-A67A-4999-BA5B-CBE38BFDE747Q38965997-7B376058-782D-4F7A-BBA8-D208D97B154DQ41849337-20E04B02-1061-46D5-AFA3-CFE422F671E2Q47366071-69E40111-2D03-4F93-979C-7E30059CE8ADQ48123571-1B2E3E53-74B2-4899-9266-54FB19610A7BQ51286509-17ED1E36-9549-41B7-AD22-E6A83FE9883B
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
H1-receptor antagonists: safety issues.
@ast
H1-receptor antagonists: safety issues.
@en
type
label
H1-receptor antagonists: safety issues.
@ast
H1-receptor antagonists: safety issues.
@en
prefLabel
H1-receptor antagonists: safety issues.
@ast
H1-receptor antagonists: safety issues.
@en
P1476
H1-receptor antagonists: safety issues.
@en
P2093
P304
P356
10.1016/S1081-1206(10)62855-4
P577
1999-11-01T00:00:00Z